Brain Metabolism Observed at 3 Tesla or 7 Tesla in Health and Metabolic Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-80
SponsorWeill Medical College of Cornell University

About this trial

The goal is to develop methodology to monitor flux in the citric acid cycle in brain via 13C nuclear magnetic resonance (NMR) spectroscopy at 7 Tesla or 3 Tesla.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Subjects will be adolescents or adults, age 16-80 years in good general health (evidenced by normal vital signs and no acute signs or symptoms of illness) or with previously (not for this study) documented G1D (genetically confirmed).

Ages 16 to 80

Persons with dental fillings, dental crowns, and short (max.4 cm) dental retainer wires can be included.

Disqualifiers

People or patients with uncontrolled seizure disorder, defined as grand mal (not absence) seizure in the preceding 3 months.

Pregnant females will be excluded. A serum or urine pregnancy test will be administered to all females of child bearing potential within 24 hours of administration of the tracer and MRI scan. The pregnancy test will be communicated in person by the study PI. Positive results in subjects 17 years old or younger will be disclosed to parent/guardian only.

Subjects with typical implanted orthopedic metal in bone may be considered for inclusion in a 7T scan providing the implant is not within the volume of the radio frequency coil. The PI and the AIRC Medical Director will discuss each case and determine eligibility.

Persons with ICD, pacemakers, neurostimulators and other such devices will be excluded.

Trial population

Adolescents and adults with Glut1 Deficiency; Normal, healthy adolescents and adults.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Magnetic resonance imaging

    Device

    Medical imaging technique used in radiology to form pictures of the anatomy.

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: Adolescents and adults with Glut1 deficiency1 intervention
Group B: Normal healthy adolescents and adults1 intervention

Trial outcomes

Primary outcomes

1

Select metabolite abundance measured at 7Tfield strength

Relative spectral amplitude at equilibrium time point (equilibrium will be defined from the spectra) of the lactate, glucose and bicarbonate spectral peaks arising from infused 13C glucose as measured by magnetic resonance spectroscopy (non contrast brain MRS 7T)

Time frame
Day 1, immediately after 13 C labeled isotope infusion
2

Select metabolite abundance measured at 3T field strength

Relative spectral amplitude at equilibrium time point (equilibrium will be defined from the spectra) of the lactate, glucose and bicarbonate spectral peaks arising from infused 13C glucose as measured by magnetic resonance spectroscopy (non contrast brain MRS 3T)

Time frame
Day 1, immediately after 13 C labeled isotope infusion

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Weill Medical College of Cornell University

Lead sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator